A drug giant is partnering with IBM to get wearables into the study of Parkinson's
Wikimedia Commons
The tech and pharma giants are partnering to develop technologies that people with Parkinson's can integrate into their daily routines with the hope that the data can help inform future treatments.
Parkinson's is characterized by motor symptoms such as shaking in the hands and legs, as well as stiffness and impaired balance, and one of the biggest problems for people who have it is keeping track of the cycles their symptoms follow. For example, tremors may be controlled better using medication at one time of day than another, something called "on" and "off" periods. Tracking that information could be critical to developing new medications to treat Parkinson's that aim to reduce the frequency of those "off" periods.
Ajay Royyuru, the director of healthcare and life sciences at IBM Research, told Business Insider that the plan is to introduce non-invasive ways to monitor the disease that don't disrupt peoples' daily lives, a group of tools they call "passive."
"Our goal is to achieve as much passive deployment as possible," said Royyuru. "The ideal scenario would be, an individual doesn't have to mess with any of the technology...and they just go about living their life. They don't have to push any buttons, they don't have to learn a new interface of any kind."
The tech could be embedded into a patient's kitchen, for example, so researchers could see how often that person cooks for themselves - a potential window into how his or her motor skills are holding up. Or it could be a wearable that tracks the patient's sleeps or movement. Having that information could determine how well a certain trial medication is working.
Peter Bergethon, Pfizer's head of quantitative medicine, said the decision to start this pharma-tech initiative in Parkinson's was for practical reasons: Pfizer has a drug for Parkinson's in development that could benefit from this kind of "internet of things" monitoring, and by putting it into an actual clinical trial, the idea is to demonstrate just how valuable this information could be.
By the end of year, IBM and Pfizer are hoping to figure out the best kinds of sensors to use, and then by 2019 Bergethon said the hope is to get the technology embedded into a Phase 3 clinical trial for one of Pfizer's Parkinson's medications.
Bergethon said this integration of tech in Parkinson's research is just the first of many, not only in neurological diseases, but potentially everything from heart conditions to cancer.
"What we're really trying to do is build a model that we can replicate," Bergethon said. "We're already talking about moving on to other neurological diseases, Alzheimer's is something we'll working on in the near future."
- Love in the time of elections: Do politics spice up or spoil dating in India?
- Samsung Galaxy S24 Plus review – the best smartphone in the S24 lineup
- Household savings dip over Rs 9 lakh cr in 3 years to Rs 14.16 lakh cr in 2022-23
- Misleading ads: SC says public figures must act with responsibility while endorsing products
- Here’s what falling inside a black hole would look like, according to a NASA supercomputer simulation
- Nothing Phone (2a) blue edition launched
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market